Current and future immunotherapy for breast cancer
NK Heater, S Warrior, J Lu - Journal of Hematology & Oncology, 2024 - Springer
Substantial therapeutic advancement has been made in the field of immunotherapy in breast
cancer. The immune checkpoint inhibitor pembrolizumab in combination with chemotherapy …
cancer. The immune checkpoint inhibitor pembrolizumab in combination with chemotherapy …
PARP inhibitors for breast cancer treatment: a review
Importance Poly (adenosine diphosphate–ribose) polymerase (PARP) inhibitors have
revolutionized the treatment of patients with germlineBRCA1/2-associated breast cancer …
revolutionized the treatment of patients with germlineBRCA1/2-associated breast cancer …
A pan‐tumor review of the role of poly (adenosine diphosphate ribose) polymerase inhibitors
Poly (adenosine diphosphate ribose) polymerase (PARP) inhibitors, such as olaparib,
talazoparib, rucaparib, and niraparib, comprise a therapeutic class that targets PARP …
talazoparib, rucaparib, and niraparib, comprise a therapeutic class that targets PARP …
Immunotherapy for Early-Stage Triple Negative Breast Cancer: Is Earlier Better?
Abstract Purpose of Review In this narrative review, we discuss the optimal timing of immune
checkpoint inhibitors (ICI) in early triple negative breast cancer (TNBC), the landscape of …
checkpoint inhibitors (ICI) in early triple negative breast cancer (TNBC), the landscape of …
New Therapeutic Options for BRCA Mutant Patients
A Ghanem, SM Domchek - Annual Review of Medicine, 2024 - annualreviews.org
Pathogenic variants in BRCA1 and BRCA2 are associated with significantly elevated lifetime
risks of breast, ovarian, pancreatic, and prostate cancer. These genes are critical in double …
risks of breast, ovarian, pancreatic, and prostate cancer. These genes are critical in double …
[HTML][HTML] Leveraging PARP-1/2 to Target Distant Metastasis
MI Frederick, D Abdesselam, A Clouvel… - International Journal of …, 2024 - mdpi.com
Poly (ADP-Ribose) Polymerase (PARP) inhibitors have changed the outcomes and
therapeutic strategy for several cancer types. As a targeted therapeutic mainly for patients …
therapeutic strategy for several cancer types. As a targeted therapeutic mainly for patients …
Phase II DORA Study of Olaparib with or without Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast …
TJ Tan, S Sammons, YH Im, L She, K Mundy… - Clinical Cancer …, 2024 - AACR
Purpose: We explored the efficacy of PARP inhibition with or without programmed death
ligand-1 (PD-L1) blockade as chemotherapy-free maintenance therapy for advanced triple …
ligand-1 (PD-L1) blockade as chemotherapy-free maintenance therapy for advanced triple …
Addressing Residual Disease in HER2-Positive and Triple-Negative Breast Cancer: What Is Next?
Purpose of review To summarize the treatment strategies for patients with human epidermal
growth factor receptor 2 (HER2)-positive disease and triple-negative breast cancer (TNBC) …
growth factor receptor 2 (HER2)-positive disease and triple-negative breast cancer (TNBC) …